MedTrace Logo

A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy Participants

NCT03885882 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-12-24

No results posted yet for this study

Summary

To assess the PK and safety after administration of three types of E0302 SR tablets (SR1, SR2, SR3) and E0302 IR tablet.

Conditions

  • Healthy Subjects

Interventions

DRUG

E0302 SR1

E0302 SR1, oral tablet.

DRUG

E0302 SR3

E0302 SR3, oral tablet.

DRUG

E0302 SR2

E0302 SR2, oral tablet.

DRUG

E0302 IR

E0302 IR, oral tablet.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-13
Primary Completion
2019-06-26
Completion
2019-06-26

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03885882 on ClinicalTrials.gov